Investigation of Gene Polymorphisms of Vaspin, Visfatin and Chemerin in Diabetic Obese and Non-Diabetic Obese Patients.

Year 2021, Volume: 5 Issue: 2, 33 - 38, 30.09.2021

Kaan Oran Arezoo Gheybi Faruk Çelik Şermin Durak , Zeliha Doğan , Büşra Aksoyer Cem Başaran Osman Fazlıogulları Nur Gökçe Çetiner Ümit Zeybek

https://doi.org/10.29228/JOHSE.9

Abstract

Diabetes mellitus and obesity are very similar in terms of pathogenesis and pathophysiology. Most obese patients have adipose tissue dysfunction caused by genetic and environmental factors. Adipose tissue is the source of adipokines secreted from adipocytes. Vaspin, Visfatin and Chemerin are adipokines discovered in recent years. The study consists of 43 non-diabetic obese and 51 diabetic obese individuals. The PCR-RFLP method and agarose gel electrophoresis techniques were used to detect gene polymorphisms of Chemerin rs17173608, Vaspin rs2236242 and Visfatin rs2110385 from DNA samples. In our study, when diabetic obese and non-diabetic obese patient groups were examined in terms of Vaspin gene polymorphism, statistically significant results were obtained (22% → 7%, p=0.048, respectively). The distribution of Chemerin or Visfatin gene variants were not different in study groups (p>0.05). Our results indicate that Chemerin rs17173608 and Visfatin rs2110385 gene polymorphisms were not risk factors for development of diabetes in obese individuals, however, Vaspin rs2236242 gene polymorphism may be a contributory risk of development of diabetes in obese individuals.

Keywords

Diabetes, Obesity, Vaspin, Chemerin, Visfatin, Polymorphism

Project Number

42096

References

• “Obesity and Overweight.” n.d. Accessed February 17, 2021. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
• Türkiye’de Obezitenin Görülme Sıklığı. n.d. Accessed February 17, 2021. https://hsgm.saglik.gov.tr/tr/obezite/turkiyede-obezitenin-gorulme-sikligi.html.
• Malik VS, Willett WC, and Hu FB. Global obesity: trends, risk factors and policy implications. Nature Reviews Endocrinology 2013.
• Bruce R, Godsland IC, Walton C, Crook D, Wynn W. Associations between insulin sensitivity, and free fatty acid and triglyceride metabolism independent of uncomplicated obesity. Metabolism 1994; 43(10):1275–81.
• Petersen KF and Shulman GI. Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. American Journal of Cardiology 2002; 90 (5 Suppl.): 11–18.
• Lago F, Dieguez C, Gómez-Reino J and Gualillo O. Adipokines as emerging mediators of immune response and inflammation. Nature Clinical Practice Rheumatology 2007
• Zorena K, Duda OJ, Ślęzak D, Robakowska M and Mrugacz M. Adipokines and obesity. potential link to metabolic disorders and chronic complications. International Journal of Molecular Sciences 2020; 21 (10): 3570.
• Pang SS and Le Y. Role of resistin in inflammation and inflammation-related diseases. Cell Mol Immunol 2006;3:29–34.
• Yu Z, Han S, Cao X, Zhu C, Wang X, and Guo X. Genetic polymorphisms in adipokine genes and the risk of obesity: a systematic review and meta-analysis. Obesity 2012; 20 (2): 396–406.
• Steppan CM and Lazar MA. 2004. The current biology of resistin. Journal of Internal Medicine 2004; 255 (4):439–47.
• Pihlajamäki J, Ylinen M, Karhapää P, Vauhkonen I and Laakso M. The effect of the − 308a allele of the tnf -α gene on insulin action is dependent on obesity. Obesity Research 2003; 11(7):912–17.
• Dimova R and Tankova T. The role of vaspin in the development of metabolic and glucose tolerance disorders and atherosclerosis. BioMed Research International. Hindawi Limited 2015.
• Antje K, Kratzsch J and Kiess W. Adipocytokines: leptin - the classical, resistin - the controversical, adiponectin - the promising, and more to come. Best Practice and Research: Clinical Endocrinology and Metabolism. Baillière Tindall 2005.
• Colhoun HM, McKeigue MP and Smith GD. Problems of reporting genetic associations with complex outcomes. Lancet. Elsevier Limited 2003.
• Pearson TA and Manolio TA. How to interpret a genome-wide association study. JAMA - Journal of the American Medical Association 2008; 299 (11): 1335–44.
• Miller S. A simple salting-out proceddure tissue for extracting dna from human nucleated cells. N Ucleic Acids Research. 1988; 16: 221.
• Hasanvand Z, Sadeghi A, Rezvanfar RM, Goodarzi MT, Rahmannezhad G and Mashayekhi FJ. Association between chemerin rs17173608 and rs4721 gene polymorphisms and gestational diabetes mellitus in iranian pregnant women. Gene 2018; 649 (April): 87–92.
• Alnory A, Hoda Gad, Hegazy G and Shaker O. The association of vaspin rs2236242 and leptin rs7799039 polymorphism with metabolic syndrome in egyptian women. Turkish Journal Of Medical Sciences 2016; 46 (5): 1335–40.
• Mirzaei K, Hossein-nezhad A, Hosseinzadeh-Attar M, Jafari N, Najmafshar A and Larijani B. Variation in the visfatin gene may alter the required dosage of oral antidiabetic agents in type 2 diabetic patients. Journal of Diabetes and Lipid Disorders 2009; Vol.8..
• Dunmore S and Brown JEP. The role of adipokines in beta-cell failure of type 2 diabetes. pituitary regulation of beta-cell function view project the effects of silibinin on glucose homeostasis and production of reactive oxygen species in c2c12 myoblasts view project the role of adipokines in b-cell failure of type 2 diabetes. Article in Journal of Endocrinology 2012.
• Nora K, Berndt J, Kralisch S, Kovacs P, Fasshauer M, Schön MR, Stumvoll M and Blüher M. 2006. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochemical and Biophysical Research Communications 2006;339(1): 430–36.
• Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, Hashimoto I, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proceedings of the National Academy of Sciences of the United States of America 2005;102(30):10610–15.
• Feng R, Li Y, Wang C, Luo C, Liu L, Chuo F, Li Q, and Sun C. Higher vaspin levels in subjects with obesity and type 2 diabetes mellitus: a meta-analysis. Diabetes Research and Clinical Practice 2014; 106(1):88–94.
• Weigert J, Neumeier M, Wanninger J, Filarsky M, Bauer S, Wiest R, Farkas S, et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clinical Endocrinology 2010; 72 (3): 342–48.
• Hetta HF, Ghada AM Marwa AG and Hala ME. Visfatin serum levels in obese type 2 diabetic patients: relation to proinflammatory cytokines and insulin resistance type 1 Diabetes Mellitus view project optimization of the effectiveness and cytocompatibility of Nigella Sativa as a co-treatment for reducing Methotrexate-related adverse effects view project. 2018.
• Sandeep S, Velmurugan K, Deepa R, and Mohan V. Serum Visfatin in Relation to Visceral Fat, Obesity, and Type 2 Diabetes Mellitus in Asian Indians. Metabolism: Clinical and Experimental 2007; 56 (4):565–70.